Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
ACE Report #9199
Ace Report Cover Spine

Kunxian capsules yields short-term clinical efficacy vs placebo for ankylosing spondylitis

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial

Trials. 2016 Jul 22;17(1):337

Contributing Authors: Q Li L Li L Bi C Xiao Z Lin S Cao Z Liao J Gu

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


80 patients with ankylosing spondylitis were randomized to receive a Chinese patent medicine, 0.6g Kunxian, or a placebo drug, 3 times daily for 12 weeks. The purpose of this study was to determine the efficacy of Kunxian, measured using the Assessment of SpondyloArthritis international Society (ASAS) 20 response rate. Other outcomes included ASAS 40, Bath Ankylosing Spondylitis Disease Activity I...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.